Robert W. Baird Reaffirms “Neutral” Rating for Medpace (NASDAQ:MEDP)

Medpace (NASDAQ:MEDP)‘s stock had its “neutral” rating reiterated by stock analysts at Robert W. Baird in a research report issued on Wednesday, Marketbeat Ratings reports. They presently have a $547.00 target price on the stock, up from their previous target price of $477.00. Robert W. Baird’s price objective would suggest a potential upside of 0.13% from the company’s current price.

Several other research firms have also issued reports on MEDP. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Royal Bank Of Canada decreased their price target on Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Weiss Ratings restated a “hold (c+)” rating on shares of Medpace in a research report on Thursday, July 2nd. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and raised their price objective for the company from $490.00 to $515.00 in a research note on Tuesday. Finally, Barclays lowered their target price on Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a research note on Friday, April 24th. Two analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $469.17.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $546.29 on Wednesday. The business has a fifty day moving average price of $460.02 and a two-hundred day moving average price of $496.16. The stock has a market capitalization of $15.60 billion, a PE ratio of 34.34, a P/E/G ratio of 2.87 and a beta of 1.15. Medpace has a fifty-two week low of $306.70 and a fifty-two week high of $628.92.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. The company had revenue of $706.60 million for the quarter, compared to analysts’ expectations of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.Medpace’s revenue was up 26.5% on a year-over-year basis. During the same quarter last year, the business earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities analysts expect that Medpace will post 17.04 EPS for the current year.

Insider Buying and Selling

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the sale, the general counsel directly owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Medpace

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geneos Wealth Management Inc. grew its stake in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Steigerwald Gordon & Koch Inc. bought a new stake in shares of Medpace in the 4th quarter valued at about $30,000. Elyxium Wealth LLC acquired a new stake in shares of Medpace in the fourth quarter valued at about $30,000. Basecamp Wealth Advisors LLC increased its stake in shares of Medpace by 187.5% in the first quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock valued at $33,000 after buying an additional 45 shares during the period. Finally, Quarry LP bought a new position in shares of Medpace during the third quarter worth about $35,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.